{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/scarlet-fever/background-information/complications/","result":{"pageContext":{"chapter":{"id":"94ffb885-96f6-595f-b1ad-fb146a27db30","slug":"complications","fullItemName":"Complications","depth":2,"htmlHeader":"<!-- begin field 4229e69c-3a38-4b02-9719-72b0d3ee8475 --><h2>What are the complications?</h2><!-- end field 4229e69c-3a38-4b02-9719-72b0d3ee8475 -->","summary":"","htmlStringContent":"<!-- begin item 21ac904a-483b-47d0-85f8-82ca8359ba71 --><!-- begin field f145498a-2ca4-4ef6-b115-34039a067e02 --><p><strong>Serious complications of scarlet fever are generally rare.</strong></p><ul><li><strong>Suppurative complications</strong><strong> are due to local spread of the infection and tend to occur early in the course of infection,</strong> and include [<a class=\"bibliography-reference internal-reference\" href=\"/topics/scarlet-fever/references/\">Wong, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/scarlet-fever/references/\">Holden, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/scarlet-fever/references/\">Wessels, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/scarlet-fever/references/\">DTB, 2018</a>]: <ul><li>Otitis media. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/otitis-media-acute/\">Otitis media - acute</a> for more information.</li><li>Throat infection and abscess (peritonsillar cellulitis, peritonsillar abscess, retropharyngeal abscess). See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/sore-throat-acute/\">Sore throat - acute</a> for more information.</li><li>Acute sinusitis and mastoiditis. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/sinusitis/\">Sinusitis</a> for more information.</li></ul></li><li><strong>Non-suppurative (immune-mediated) complications</strong><strong> tend to occur later in the course of infection,</strong> particularly in untreated people, and include [<a class=\"bibliography-reference internal-reference\" href=\"/topics/scarlet-fever/references/\">Wong, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/scarlet-fever/references/\">Holden, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/scarlet-fever/references/\">Wessels, 2016</a>]: <ul><li>Acute rheumatic fever — this is an immunologically-mediated response and can cause carditis and endocarditis (leading to valvular heart disease) and reactive arthritis.</li><li>Acute post-streptococcal glomerulonephritis — this typically occurs 2 weeks or more after the acute initial infection, and may present with haematuria, reduced urine output, peripheral oedema, proteinuria, and hypertension. Permanent kidney damage is rare.</li></ul></li><li><strong>Invasive Group A streptococcal (iGAS) infections may be life-threatening and include </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/scarlet-fever/references/\">Wong, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/scarlet-fever/references/\">Wessels, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/scarlet-fever/references/\">DTB, 2018</a>]<strong>:</strong><ul><li>Streptococcal pneumonia. See the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/cough-acute-with-chest-signs-in-children/\">Cough - acute with chest signs in children</a> and <a class=\"topic-reference external-reference\" href=\"/topics/chest-infections-adult/\">Chest infections - adult</a> for more information.</li><li>Meningitis and cerebral abscess. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/meningitis-bacterial-meningitis-meningococcal-disease/\">Meningitis - bacterial meningitis and meningococcal disease</a> for more information.</li><li>Endocarditis, septic arthritis, and liver abscess.</li><li>Cellulitis, necrotizing fasciitis, and streptococcal toxic shock syndrome. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/cellulitis-acute/\">Cellulitis - acute</a> for more information.</li><li>Sepsis. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/sepsis/\">Sepsis</a> for more information.</li><li>Risk of death —  severe iGAS infections carry a substantial risk of mortality (around 15–25%).</li></ul></li></ul><!-- end field f145498a-2ca4-4ef6-b115-34039a067e02 --><!-- end item 21ac904a-483b-47d0-85f8-82ca8359ba71 -->","topic":{"id":"7c05f7c5-902d-5982-8cc9-5f1d301d214d","topicId":"f534013d-38dd-4f96-bc65-37091262952c","topicName":"Scarlet fever","slug":"scarlet-fever","lastRevised":"Last revised in March 2020","chapters":[{"id":"d3f6c278-a759-50f3-9a96-734913f439ab","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"ffff4a88-7ddf-55dc-a37b-1625f3f58e2b","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"89be33c0-acbe-51fd-901b-d7cf571435a4","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"61377ddb-df7a-50fb-9dd7-224014332a4e","slug":"changes","fullItemName":"Changes"},{"id":"b5e95aca-9003-52f8-b6e7-0c192c5ba757","slug":"update","fullItemName":"Update"}]},{"id":"90d2085f-63f5-57a1-b21e-21d4c580229a","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"cc3aa630-ef6b-5504-9439-6a4757e7fe43","slug":"goals","fullItemName":"Goals"},{"id":"ebf64432-58f2-513f-a393-ec4e8438f355","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"b3da9abe-7cc8-5c97-970d-39b1416de8cb","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"8b3309e1-1d9f-520e-b310-592706c0951d","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"0603af50-edd7-5e78-a394-1fd6a1a1af21","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"00da52ed-356a-563d-aa3c-dc4e3ee27155","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"7072120a-72ec-5945-b4f0-e4386374e1ad","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"f61354f7-80ff-5483-89fc-51be1d57b5d3","slug":"definition","fullItemName":"Definition"},{"id":"4dc22989-c1d3-5880-a381-78cabd38ca4d","slug":"transmission","fullItemName":"Transmission"},{"id":"c4e4e4ff-9b93-5d55-8ae0-5e0b1a518ef3","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"5b31f083-75b7-5ae3-9029-87df9bc061cf","slug":"prevalence","fullItemName":"Prevalence"},{"id":"94ffb885-96f6-595f-b1ad-fb146a27db30","slug":"complications","fullItemName":"Complications"},{"id":"f3bf38a0-7946-504a-b22c-654728a0366a","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"ffb84f0d-77eb-5011-a50d-14d9143e4bd4","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"8484304f-9507-5401-8c08-2c93126a8b3f","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"601ddd63-7670-5740-a0f6-fe317e0d7770","slug":"investigations","fullItemName":"Investigations"},{"id":"a1df37ba-9251-52d5-8376-b19803e39cc3","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"5329e2f2-3618-5113-8fc1-5228ff864869","fullItemName":"Management","slug":"management","subChapters":[{"id":"963d805b-33a2-5e78-9195-323379519c7e","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"db4a097c-9d97-5e1e-8718-e082e8e25f5e","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"4a26593a-c9e4-5523-a6d2-5feb274dcf79","slug":"phenoxymethylpenicillin","fullItemName":"Phenoxymethylpenicillin"},{"id":"2a494a84-0688-5337-8f03-a2ab33a654fb","slug":"amoxicillin","fullItemName":"Amoxicillin"},{"id":"ce256942-e7de-5014-bdf7-f34be5755538","slug":"azithromycin","fullItemName":"Azithromycin"}]},{"id":"7e3b4438-f437-5199-8ee5-f3c9d210b732","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"f2446794-c34e-574f-8de3-c5ecbe3c4f35","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"1a90ff7f-b2b6-5959-86a0-3cea6609706f","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"0d14df6f-1299-58da-b620-c970e5b90b91","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"db42b54d-b095-52b7-9cb1-37d73c57fdb7","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"551dac2a-e65d-57c4-b16c-279891510a2b","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"5d76e530-4218-5600-a9ed-896a3245aefb","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"03221ed8-00f7-5819-b90c-cc69c4a1fdb8","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"7072120a-72ec-5945-b4f0-e4386374e1ad","slug":"background-information","fullItemName":"Background information"},"subChapters":[]}}},"staticQueryHashes":["3666801979"]}